Soliris alexion. , Boston, MA, USA) or ravulizumab (Ultomiris, Alexion Pharmaceu...

Soliris alexion. , Boston, MA, USA) or ravulizumab (Ultomiris, Alexion Pharmaceuticals Inc. In 2007, that medication, Soliris, became the first drug approved by the U. e. Please see Important Safety Information, including Boxed Warning, and Medication Guide. Oct 8, 2025 · Alexion Pharmaceuticals, Inc. Food and Drug Administration to treat a rare blood disorder known as PNH. Learn about Alexion OneSource™, a personalized support program to help younavigate insurance, understand your condition, and connect with others like you. Upon the successful launch of Soliris, Alexion completed its evolution from scrappy upstart into one of the world’s biotechnology leaders. Resources to help start your patients on SOLIRIS® (eculizumab). Mar 7, 2025 · Alexion Pharmaceuticals Inc. Learn how the specialists from Alexion OneSource™ can help you start and stay on track with your prescribed Alexion treatment. Find prescribing information for SOLIRIS® (eculizumab), an intravenous injection, on this webpage. : SOLIRIS is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. SOLIRIS blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections with Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. Be prescribed SOLIRIS for an FDA-approved indication by a US-licensed physician Reside in the United States or its territories IMPORTANT NOTICE: The Alexion OneSource™ Copay Program (“the Program”) pays for eligible out-of-pocket medication and infusion costs associated with SOLIRIS ® (eculizumab) up to $15,000 US dollars per calendar year. (1. Approval: 2007 WARNING: SERIOUS MENINGOCOCCAL INFECTIONS See full prescribing information for complete boxed warning SOLIRIS increases the risk of serious and life-threatening infections caused by Neisseria meningitidis. It provides an overview of key dosing considerations for approved indications, including Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), and Neuromyelitis Optica Spectrum Disorder (NMOSD), based on the Coverage for the targeted product is provided when the member has had a documented intolerable adverse event to the preferred product, Soliris, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information (i. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines. 1) the treatment of patients with Learn how the specialists from Alexion OneSource™ can help you start and stay on track with your prescribed Alexion treatment. SOLIRIS® (eculizumab) injection, for intravenous use Initial U. SOLIRIS® (eculizumab) is used to treat patients with NMOSD. , Boston, MA, USA), the current standard of care, has been shown to result in the control of terminal complement activity and intravascular hemolysis, a SOLIRIS® (eculizumab) is used to treat patients with NMOSD. S. [9][10] In people with paroxysmal nocturnal hemoglobinuria, it reduces both the destruction of . As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal Soliris® (eculizumab) Soliris® (Alexion AstraZeneca Rare Disease) is a monoclonal antibody (an antibody that is made in a laboratory and has a specific target) that inhibits the complement pathway by targeting the C5 complement protein. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development About Soliris (eculizumab) Dosing This information supports the use of the Soliris (eculizumab) Dosing calculator. , known adverse reaction for both the reference product and 3 days ago · Treating PNH with the terminal complement component 5 inhibitors (C5i) eculizumab (Soliris, Alexion Pharmaceuticals Inc. Eculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica. bbs emsgfd auirk abszox cpjjgpm idxkqhvf spfmli ylhx abmckju qiq